Navigation Links
Veran Medical Technologies Completes Financing Worth More Than $15 Million
Date:3/18/2011

ST LOUIS, March 18, 2011 /PRNewswire/ -- Veran Medical Technologies announced today that it has completed a round of financing worth more than $15M. Participants in the financing included existing investors and a new strategic partner. The proceeds from this financing will be used to commercialize products on the IG4 four-dimensional image guidance platform of technology.

"We are pleased to secure this funding as it will enable us to rapidly commercialize the products we are building and continue to impact patient care in an effort to diagnose and treat cancer earlier," said Jerome Edwards, president and CEO.

About Veran Medical Technologies, Inc.

Veran Medical Technologies is a privately held company led by a team of ex-Medtronic innovators focused on developing the next standard of care for minimally invasive delivery of interventional oncology therapies. Veran has built several clinical products upon its IG4 platform technology, which uses proprietary 4-D registration capabilities for targeting lesions within the human body. The company believes that by enabling minimally invasive, early stage treatments, it can increase patient survival and lower Healthcare Costs significantly. Veran is headquartered in St. Louis, MO.


'/>"/>
SOURCE Veran Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Veran Medical Technologies First SPiN Drive Installation at Duke Medical Center
2. Aegis Analytical Corp. Showcases Discoverant at Inaugural Venture Capital in the Rockies Fall
3. Boveran Diagnostics, Inc. Announces Planned Acquisition of New York-Based Pathology Lab: Sophora Diagnostic Lab, Inc.
4. Investing in Biomedical Innovation
5. Informed Medical Communications and IC Axon Merge Creating a Full Complement of Training and Marketing Services
6. OncoSec Medical Appoints Punit Dhillon as President and CEO
7. Argentum Medical Issues Response to Recent Decision in Litigation With Noble Biomaterials
8. D3 Oncology Solutions Now Includes Via Oncology Pathways for Medical Oncology
9. WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
10. Sensus Healthcare Announces the Formation of a Medical Advisory Board
11. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):